Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis.
We embrace a philosophy of scientific entrepreneurship which spurs innovation and empowers and inspires our people to discover, develop and commercialize transformative therapies which can make a meaningful difference in the lives of patients.
Co-founders, Dr. Clayman and Dr. Bodick leveraged the extensive drug development expertise they gained over decades at Eli Lilly and Company to establish Flexion in 2007.
They are complemented by an executive committee comprised of industry veterans who possess deep knowledge, vast experience and the diverse leadership skills required in the biopharma industry. Furthermore we have assembled a robust commercial organization with a team of leaders who have successfully launched multiple products in the musculoskeletal space.
